Biotech Startups

Dianthus Therapeutics develops antibody-based therapies for patients with severe autoimmune diseases, including its lead complement C1s inhibitor claseprubart (DNTH103) and a bifunctional inhibitor DNTH212 designed for self-administered subcutaneous injection. The company operates in the biotech and drug development sector.

1 investor

Diasome develops metabolic therapies using its HDV platform to enable targeted drug delivery for treating diabetes, obesity, and metabolic diseases. The company focuses on translating therapeutic insights to restore metabolic function using endogenous mechanisms.

1 investor

Diatech Pharmacogenetics provides molecular testing and genetic analysis to enable precision medicine by matching patients with appropriate therapies based on their individual genetic profiles. The company serves healthcare providers and patients seeking personalized treatment options informed by pharmacogenomic data.

1 investor

DIATER develops diagnostic tools and therapeutic treatments for allergy patients using molecular immunotherapy techniques. The company manufactures personalized therapies for complex allergies and operates across Spain, Portugal, and Germany.

1 investor

Diesse develops and manufactures in-vitro diagnostic instruments and reagents for clinical laboratories, including automated ESR (erythrocyte sedimentation rate) analyzers, automated and manual immunoassay systems, and rapid diagnostic tests. Its product lines include VES-MATIC, CHORUS, AUTO-DAT, Enzywell, and iRapid.

1 investor

Differential Bio offers a virtual scale-up platform for bioprocess optimization, using robotic lab automation to gather microliter-scale fermentation data and AI models to simulate and optimize microbial growth, yield, and cost. It serves biotech and industrial fermentation R&D teams looking to derisk and accelerate strain and process development before large-scale production.

1 investor

1 investor

DiFusion develops therapeutic biomaterials for medical device applications, combining material science, biological research, and clinical evidence. Its flagship material, ZFUZE, is a load-bearing biomaterial engineered to influence the healing environment at the implant surface, used in spinal interbody and other orthopedic implant platforms through partnerships with medical device OEMs.

1 investor

Digestiva develops proprietary protease enzymes that break down proteins to produce more bioaccessible and smaller peptides, increase free amino acid availability, and improve protein yield from co-products and waste streams. Its technology targets applications in health, nutrition, and food processing.

1 investor

Digi.Bio develops a single-cell, AI-driven, lab-on-a-chip platform that profiles the fate and performance of individual cells to evaluate how therapies perform over time. The technology, aimed at drug developers working on cell-based and immune therapies, measures cytotoxicity, cell motility, and cell-cell interactions to compare drug efficacy.

1 investor

DigiBiomics offers an AI-based respiratory screening and monitoring platform that analyzes cough sounds, clinical symptoms, and medical imaging to detect early signs of lung disease and generate a risk score at the point of care. It is aimed at clinical settings where lab tests or specialists may not be readily available.

1 investor

Digital Biology (Digit Bio) develops precision biologics and combination therapies for solid tumors, using its M×P (Molecules × Phenotypes) Platform that combines high-resolution imaging, next-generation sequencing, computation, and AI to map the spatial molecular organization of tumor tissues. The company applies this measurement technology to discover spatially synergistic tumor antigen targets for immunotherapies and partners with pharmaceutical companies and foundations in precision oncology.

1 investor

Dilafor is a clinical-stage pharmaceutical company developing tafoxiparin, a proprietary heparan sulfate mimetic drug candidate intended to improve cervical ripening and support efficient labor in term pregnant women. The drug aims to reduce complications associated with planned start of labor, and is based on research from Karolinska Institute and Lund University.

1 investor

A biotech company using AI and dynamic blood biomarkers to develop precision therapeutics for immunology.

1 investor

Diploid Genomics uses phased diploid genome sequencing combined with multimodal clinical data and AI to detect disease earlier and guide personalized care. The company integrates genomic, imaging, and clinical data into a precision health platform designed for healthcare systems, specialty clinics, and biopharma partners.

1 investor

DiscGenics develops an allogeneic, injectable disc progenitor cell therapy (IDCT/rebonuputemcel) for painful lumbar degenerative disc disease, currently advancing toward a Phase III clinical program. The company works in regenerative spine medicine and cell therapy, and collaborates on tissue-engineered intervertebral disc research.

1 investor

Eurofins DiscoverX develops and manufactures cell-based assays, engineered cell lines, recombinant proteins, enzymes, and reagents used in drug discovery and development, including screening, potency testing, and QC lot release. As the products division of Eurofins Discovery, it serves biopharmaceutical and therapeutic drug development programs from manufacturing sites in the USA and France.

1 investor

Dispatch Bio develops a universal immunotherapy treatment for solid tumors, combining engineered immunotherapy with a tumor-specific virus to improve cancer treatment outcomes.

1 investor

Disruptive Pharma is a pharmaceutical technology company that develops and commercializes a patented formulation platform aimed at improving the solubility, oral bioavailability, and other properties of drug compounds. Its technology also targets smaller pill sizes and more environmentally friendly manufacturing.

1 investor

DLeader develops an AI-powered platform for automated drug discovery that accelerates the research and development process for pharmaceutical researchers. The platform uses generative AI tools to support and optimize the drug discovery workflow.

1 investor

DNA Gensee runs a DNA analysis laboratory and R&D consultancy that identifies plant and algae species in raw materials, ingredients, and finished products using molecular biology techniques. It serves industrial manufacturers using plants or algae, verifying botanical and geographic authenticity, traceability, safety, and quality of natural extracts.

1 investor

DNASequence is a biotech company using metagenomic sequencing and bioinformatics to provide pathogen detection, microbiome analysis, and environmental monitoring. It serves healthcare providers, research institutions, and public/environmental agencies, operating an ISO/IEC 17025:2017-accredited metagenomics laboratory.

1 investor

DName-it provides quality assurance for genetic testing by embedding molecular-level DNA identity markers into samples that travel through NGS-based workflows from collection to sequencing. The system automatically verifies sample identity and detects errors such as sample switching, mislabeling, and cross-contamination during sequencing analysis, serving genetic testing labs.

1 investor

DNAsimple connects individuals with medical research studies, matching them to researchers' requests and paying rewards for contributing biological samples (blood, urine) and completing health surveys. It lets participants share their medical records and de-identified health data, and complete studies at home or with a visiting clinician.

1 investor